Insights into serotonin signal ing mechanisms associated with canine degenerative mitral valve disease

Journal of Veterinary Internal Medicine

Volumn 24, Issue 1, 2010, Pages 27-36

  Oyama, M A ^a   Levy, R J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cellular biochemistry; Molecular biology; Physiology; Valvular disease

Indexed keywords

ANIMALIA;

SEROTONIN;

ANIMAL; ANIMAL DISEASE; DOG; DOG DISEASE; METABOLISM; MITRAL VALVE REGURGITATION; REVIEW;

ANIMALS; DOG DISEASES; DOGS; MITRAL VALVE INSUFFICIENCY; SEROTONIN;

EID: 73349142054     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2009.0411.x     Document Type: Article

References (95)

1. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associ- ated with fenfluramine. Mol Pharmacol 2000;57:75-81.
2. Fox DJ, Khattar RS. Carcinoid heart disease: Presentation, diagnosis, and management. Heart 2004;90:1224-1228.
3. Gustafsson BI, Hauso O, Drozdov I, et al. Carcinoid heart disease. Int J Cardiol 2008;129:318-324.
4. Ramage AG, Villalon CM. 5-hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci 2008;29:472-481.
5. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvu- lopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-2841.
6. Levy FO, Qvigstad E, Krobert KA, et al. Effects of serotonin in failing cardiac ventricle: Signalling mechanisms and potential therapeutic implications. Neuropharmacology 2008;55:1066-1071.
7. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-829.
8. Hofmann C, Penner U, Dorow R, et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: Ab- sence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 2006;29:80-86.
9. Sachdev M, Miller WC, Ryan T, et al. Effect of fenfluramine- derivative diet pills on cardiac valves: A meta-analysis of observa- tional studies. Am Heart J 2002;144:1065-1073.
10. Droogmans S, Franken PR, Garbar C, et al. In vivo model of drug-induced valvular heart disease in rats: Pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. Eur Heart J 2007;28:2156-2162.
11. Elangbam CS, Job LE, Zadrozny LM, et al. 5-hydroxytry- ptamine (5HT)-induced valvulopathy: Compositional valvular alterations are associated with 5HT2B receptor and 5HT trans- porter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 2008;60:253-262.
12. Guilbert F, Lainee P, Dubreuil B, et al. Serotonin aggravates exercise-induced cardiac ischemia in the dog: Effect of serotonin re- ceptor antagonists. Eur J Pharmacol 2004;497:55-63.
13. Gustafsson BI, Tommeras K, Nordrum I, et al. Long-term serotonin administration induces heart valve disease in rats. Circu- lation 2005;111:1517-1522.
14. Jaffre F, Callebert J, Sarre A, et al. Involvement of the sero- tonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: Control of interleukin-6, interleukin- 1beta, and tumor necrosis factor-alpha cytokine production by ven- tricular fibroblasts. Circulation 2004;110:969-974.
15. Mekontso-Dessap A, Brouri F, Pascal O, et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 2006;113:81-89.
16. Nebigil CG, Jaffre F, Messaddeq N, et al. Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy. Circulation 2003;107:3223-3229.
17. Xu J, Jian B, Chu R, et al. Serotonin mechanisms in heart valve disease II: The 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol 2002;161:2209-2218.
18. Detweiler DK, Patterson DF. The prevalence and types of cardiovascular disease in dogs. Ann NY Acad Sci 1965;127:481-516.
19. Buchanan JW. Chronic valvular disease (endocardiosis) in dogs. Adv Vet Sci Comp Med 1977;21:75-106.
20. Buchanan JW. Prevalance of cardiac disorders. In: Fox PR, Sisson DD, Moise NS, eds. Textbook of Canine and Feline Cardi- ology, 2nd ed. Philadelphia, PA: WB Saunders; 1999:457-470.
21. Aupperle H, Marz I, Thielebein J, et al. Immunohistochem- ical characterization of the extracellular matrix in normal mitral valves and in chronic valve disease (endocardiosis) in dogs. Res Vet Sci 2009;87:277-283.
22. Haggstrom J, Duelund PH, Kvart C. New insights into de- generative mitral valve disease in dogs. Vet Clin North Am Small Anim Pract 2004;34:1209-1226.
23. Hadian M, Corcoran BM, Han RI, et al. Collagen organiza- tion in canine myxomatous mitral valve disease: An X-ray diffraction study. Biophys J 2007;93:2472-2476.
24. Black A, French AT, Dukes-McEwan J, et al. Ultrastructural morphologic evaluation of the phenotype of valvular interstitial cells in dogs with myxomatous degeneration of the mitral valve. Am J Vet Res 2005;66:1408-1414.
25. Donnelly KB. Cardiac valvular pathology: Comparative pa- thology and animal models of acquired cardiac valvular diseases. Toxicol Pathol 2008;36:204-217.
26. Prunotto M, Caimmi PP, Bongiovanni M. Cellular pathol- ogy of mitral valve prolapse. Cardiovasc Pathol 2009, doi: 10.1016/ j.carpath.2009.03.002.
27. Blevins TL, Carroll JL, Raza AM, et al. Phenotypic charac- terization of isolated valvular interstitial cell subpopulations. J Heart Valve Dis 2006;15:815-822.
28. Disatian S, Ehrhart EJ III, Zimmerman S, et al. Interstitial cells from dogs with naturally occurring myxomatous mitral valve disease undergo phenotype transformation. J Heart Valve Dis 2008;17:402-411.
29. Jian B, Xu J, Connolly J, et al. Serotonin mechanisms in heart valve disease I: Serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal trans duction in aortic valve interstitial cells. Am J Pathol 2002;161: 2111-2121.
30. Serini G, Gabbiani G. Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res 1999;250: 273-283.
31. Mow T, Pedersen HD. Increased endothelin-receptor density in myxomatous canine mitral valve leaflets. J Cardiovasc Pharma- col 1999;34:254-260.
32. Pedersen HD, Schutt T, Sondergaard R, et al. Decreased plasma concentration of nitric oxide metabolites in dogs with untreated mitral regurgitation. J Vet Intern Med 2003;17:178-184.
33. Muneoka Y, Fujisawa Y, Matsuura M, et al. Neurotransmitters and neuromodulators controlling the anterior byssus retractor muscle of Mytilus edulis. Comp Biochem Physiol C 1991;98:105-114.
34. Gainey LF Jr, Walton JC, Greenberg MJ. Branchial muscu- lature of a venerid clam: Pharmacology, distribution, and innervation. Biol Bull 2003;204:81-95.
35. D'yakonova TL. Interaction between serotonin and nitric oxide (NO) in the activation of the serotoninergic system in the common snail. Neurosci Behav Physiol 2002;32:275-282.
36. Monti JM, Jantos H. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking. Prog Brain Res 2008;172:625-46.
37. Gonzalez-Burgos I, Feria-Velasco A. Serotonin/dopamine interaction in memory formation. Prog Brain Res 2008;172:603-23.
38. Ryding E, Lindstrom M, Traskman-Bendz L. The role of dopamine and serotonin in suicidal behaviour and aggression. Prog Brain Res 2008;172:307-15.
39. Jonnakuty C, Gragnoli C. What do we know about serotonin? J Cell Physiol 2008;217:301-306.
40. Ni W, Watts SW. 5-hydroxytryptamine in the cardiovascular system: Focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol 2006;33:575-583.
41. Meyers KM, Holmsen H, Seachord CL. Comparative study of platelet dense granule constituents. Am J Physiol 1982;243:R454-R461.
42. Sari Y, Zhou FC. Serotonin and its transporter on prolifer- ation of fetal heart cells. Int J Dev Neurosci 2003;21:417-424.
43. Pavone LM, Spina A, Lo MR, et al. Heart valve card- iomyocytes of mouse embryos express the serotonin transporter SERT. Biochem Biophys Res Commun 2008;377:419-422.
44. Molinoff PB, Axelrod J. Biochemistry of catecholamines. Annu Rev Biochem 1971;40:465-500.
45. Kaumann AJ, Levy FO. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 2006;111:674-706.
46. Roy A, Brand NJ, Yacoub MH. Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves. J Heart Valve Dis 2000;9:256-260.
47. Oyama MA, Chittur SV. Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve dis- ease. Am J Vet Res 2006;67:1307-1318.
48. Disatian S, Orton EC. Autocrine serotonin and transforming growth factor b1 signaling mediates spontaneous myxomatous mi- tral valve disease. J Heart Valve Dis 2009;18:44-51.
49. Cushing MC, Liao JT, Anseth KS. Activation of valvular interstitial cells is mediated by transforming growth factor-beta1 in- teractions with matrix molecules. Matrix Biol 2005;24:428-437.
50. Walker GA, Masters KS, Shah DN, et al. Valvular myofi- broblast activation by transforming growth factor-beta: Implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res 2004;95:253-260.
51. Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 pa- tients. Circulation 1993;87:1188-1196.
52. Simula DV, Edwards WD, Tazelaar HD, et al. Surgical pa- thology of carcinoid heart disease: A study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc 2002;77:139-147.
53. Rajamannan NM, Caplice N, Anthikad F, et al. Cell prolif- eration in carcinoid valve disease: A mechanism for serotonin effects. J Heart Valve Dis 2001;10:827-831.
54. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnor- malities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790-795.
55. Patnaik AK, Hurvitz AI, Johnson GF. Canine intestinal ad- enocarcinoma and carcinoid. Vet Pathol 1980;17:149-163.
56. Sako T, Uchida E, Okamoto M, et al. Immunohistochemical evaluation of a malignant intestinal carcinoid in a dog. Vet Pathol 2003;40:212-215.
57. Sykes GP, Cooper BJ. Canine intestinal carcinoids. Vet Pa- thol 1982;19:120-131.
58. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588.
59. Setola V, Dukat M, Glennon RA, et al. Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor. Mol Pharmacol 2005;68:20-33.
60. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. Mov Disord 2004;19:656-662.
61. Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4-methylenedioxymethamphetamine (MDMA, ''Ecstasy'') induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003;63:1223-1229.
62. Rothman RB, Baumann MH. Appetite suppressants, car- diac valve disease and combination pharmacotherapy. Am J Ther 2009;16:354-364.
63. Zolkowska D, Baumann MH, Rothman RB. Chronic fen- fluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels. J Pharmacol Exp Ther 2008;324:791-797.
64. Hauso O, Gustafsson BI, Loennechen JP, et al. Long-term serotonin effects in the rat are prevented by terguride. Regul Pept 2007;143:39-46.
65. Connolly JM, Bakay MA, Fulmer JT, et al. Fenfluramine disrupts the mitral valve interstitial cell response to serotonin. Am J Pathol 2009;175:988-997.
66. Arndt JW, Oyama MA, Connolly JM, et al. Serum serotonin concentration is elevated in dogs with degenerative mitral valve disease. J Vet Intern Med 2009; doi: 10.1111/j.1939-1676.2009. 0378.x;22:717.
67. Yabanoglu S, Akkiki M, Seguelas MH, et al. Platelet derived serotonin drives the activation of rat cardiac fibroblasts by 5-HT2A receptors. J Mol Cell Cardiol 2009;46:518-525.
68. Corcoran BM, Black A, Anderson H, et al. Identification of surface morphologic changes in the mitral valve leaflets and chordae tendineae of dogs with myxomatous degeneration. Am J Vet Res 2004;65:198-206.
69. Riddle JM, Wang CH, Magilligan DJ Jr, et al. Scanning electron microscopy of surgically excised human mitral valves in patients over 45 years of age. Am J Cardiol 1989;63:471-477.
70. Stein PD, Wang CH, Riddle JM, et al. Scanning electron mi- croscopy of operatively excised severely regurgitant floppy mitral valves. Am J Cardiol 1989;64:392-394.
71. Tanaka R, Yamane Y. Platelet aggregation in dogs with mi- tral valve regurgitation. Am J Vet Res 2000;61:1248-1251.
72. Olsen LH, Kristensen AT, Haggstrom J, et al. Increased platelet aggregation response in Cavalier King Charles Spaniels with mitral valve prolapse. J Vet Intern Med 2001;15:209-216.
73. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621-2624.
74. Ogilvie AD, Battersby S, Bubb VJ, et al. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 1996;347:731-733.
75. Sutcliffe JS, Delahanty RJ, Prasad HC, et al. Allelic hetero- geneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. Am J Hum Genet 2005;77:265-279.
76. Lesch KP, Bengel D, Heils A, et al. Association of anxiety- related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531.
77. Greenberg BD, Tolliver TJ, Huang SJ, et al. Genetic variation in the serotonin transporter promoter region affects sero- tonin uptake in human blood platelets. Am J Med Genet 1999;88:83-87.
78. Serretti A, Calati R, Mandelli L, et al. Serotonin transporter gene variants and behavior: A comprehensive review. Curr Drug Targets 2006;7:1659-1669.
79. Lesch KP, Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1062-1073.
80. Aupperle H, Marz I, Thielebein J, et al. Expression of trans- forming growth factor-beta1, -beta2 and -beta3 in normal and diseased canine mitral valves. J Comp Pathol 2008;139:97-107.
81. Khan R, Sheppard R. Fibrosis in heart disease: Understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006;118:10-24.
82. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18:816-827.
83. Liu AC, Gotlieb AI. Transforming growth factor-beta regu- lates in vitro heart valve repair by activated valve interstitial cells. Am J Pathol 2008;173:1275-1285.
84. Merryman WD, Lukoff HD, Long RA, et al. Synergistic ef- fects of cyclic tension and transforming growth factor-beta1 on the aortic valve myofibroblast. Cardiovasc Pathol 2007;16:268-276.
85. Sucosky P, Balachandran K, Elhammali A, et al. Altered shear stress stimulates upregulation of endothelial VCAM-1 and ICAM-1 in a BMP-4- and TGF-beta1-dependent pathway. Ar- terioscler Thromb Vasc Biol 2009;29:254-260.
86. Zuetenhorst JM, Bonfrer JM, Korse CM, et al. Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excre- tion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 2003;97:1609-1615.
87. Waltenberger J, Lundin L, Oberg K, et al. Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am J Pathol 1993;142:71-78.
88. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991;352:337-339.
89. Stuart AG, Williams A. Marfan's syndrome and the heart. Arch Dis Child 2007;92:351-356.
90. Yosefy C, Ben Barak A. Floppy mitral valve/mitral valve prolapse and genetics. J Heart Valve Dis 2007;16:590-595.
91. Zangwill SD, Brown MD, Bryke CR, et al. Marfan syn- drome type II: There is more to Marfan syndrome than fibrillin 1. Congenit Heart Dis 2006;1:229-232.
92. Kalluri R, Han Y. Targeting TGF-beta and the extracellular matrix in Marfan's syndrome. Dev Cell 2008;15:1-2.
93. Judge DP, Dietz HC. Therapy of Marfan syndrome. Annu Rev Med 2008;59:43-59.
94. Zheng J, Chen Y, Pat B, et al. Microarray identifies extensive downregulation of noncollagen extracellular matrix and profibrotic growth factor genes in chronic isolated mitral regurgitation in the dog. Circulation 2009;119:2086-2095.
95. Mast ST, Gersing KR, Anstrom KJ, et al. Association be- tween selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. Am J Cardiol 2001;87:989-993.